Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-P13 study in children with newly diagnosed acute promyelocytic leukemia
jRCTs051180191Phase 2Completed
- Start
- Jan 2015
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and gemtuzumab ozogamicin in Acute promyelocytic leukaemia (APL). Primary endpoint: Three-year event-free survival rate. Started Jan 2015; status: completed.
02
Drugs
arsenic trioxidegemtuzumab ozogamicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on jRCTs051180191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180191.